Intranasal Oxytocin (IN-OXT)
2020P003071
Phase 1 small_molecule active
Quick answer
Intranasal Oxytocin (IN-OXT) for Vasopressin Deficiency is a Phase 1 program (small_molecule) at Tonix Pharmaceuticals Holding with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Tonix Pharmaceuticals Holding
- Indication
- Vasopressin Deficiency
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active